Texas
LATEST FROM BIOSPACE
A recent study questions if the FDA and other regulatory agencies worldwide rush certain approvals, particularly at the end of the year in a kind of “desk-clearing” activity.
BioSpace spoke to leaders from various corners of the industry who provided their insights into what the coming year is likely to hold for their particular sphere.
“We are pleased that the FDA recognized Molgradex as a breakthrough therapy for the treatment of aPAP, a debilitating rare lung disease with no approved pharmacologic treatment options,” said Rob Neville, Savara’s chief executive officer.
What they found was that melanoma cells are more likely to metastasize through the body if their cells have high concentrations of MCT1 on their cell surface.
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s hires.
In March, the FDA issued a Complete Response Letter for Zynquista as a treatment for type 1 diabetes.
In light of the Thanksgiving season, here are six things about biopharma that we are thankful for.
With the Thanksgiving holiday fast-approaching in the United States, some investors are giving their thanks to five different pharma companies that became available on the stock exchange this month with an initial public offering.
Some analysts are checking their crystal balls to get an idea if 2020 will be a busy year for investors. The early thinking on biotech is yes.
PRESS RELEASES